Dr. Reddy’s Laboratories Ltd ADR (RDY)

Sep 25, 2026

Dr. Reddy's Laboratories Ltd. saw a modest gain of 0.20% on Friday, reaching 1,202.80 Indian rupees, despite an overall positive trading session where the BSE SENSEX Index rose by 0.43%. The company's stock closed significantly below its 52-week high, indicating an underperformance compared to the broader market. This report was generated by MarketWatch Automation, supported by data from Dow Jones and FactSet.

Sep 23, 2026

Nykredit A/S has acquired a new position in Dr. Reddy's Laboratories Ltd (NYSE:RDY), purchasing 111,102 shares valued at approximately $1.61 million during the second quarter. Despite several institutional investors increasing their stakes, hedge funds and other institutions collectively own only 3.85% of the stock. Analysts currently maintain a "Reduce" rating on the stock, following the company missing its quarterly earnings estimates with $0.06 per share against an estimated $0.09.

Sep 21, 2026

Dr. Reddy’s Laboratories Ltd (RDY) is a global pharmaceutical company with a market capitalization of $10.15 billion, currently trading at $12.19. Despite revenue growth challenges and negative free cash flow, the company shows a 9.6% potential upside according to analyst targets, a respectable return on equity of 8.84%, and a dividend yield of 0.68%. Technical indicators suggest the stock is nearing oversold territory, potentially offering a buying opportunity.

Sep 17, 2026

Dr Reddy's Laboratories has announced a distribution agreement with Takeda Pharmaceutical Company for the promotion and distribution of the Qdenga dengue vaccine in India. The deal was signed on Friday. The collaboration aims to make the dengue vaccine available across India.

Sep 15, 2026

Dr. Reddy's Laboratories (500124) shares dropped 0.97% to 1,149.75 Indian rupees on Tuesday, despite an overall dismal trading session for the stock market which saw the BSE SENSEX Index (1) fall 1.04%. The company's stock closed 18.71% below its 52-week high achieved on June 29th.